GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Candel Therapeutics
Candel Therapeutics is a biotech company developing oncolytic viruses for cancer treatment. Its stock price represents a venture bet on the success of this innovative approach. The chart reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - Cancer cure
Candel Therapeutics (CADL) is a biopharmaceutical company developing oncolytic viral immunotherapies for the treatment of various cancers, including prostate cancer and glioblastoma. We classify the company under the "Cancer Treatment" category. The chart below illustrates the dynamics of this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
Candel Therapeutics is a biopharmaceutical company developing viral immunotherapy for cancer treatment. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Candel compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CADL - Daily change in the company's share price Candel Therapeutics
Shares of Candel, an oncology company, are highly volatile. Change_co measures the market reaction to clinical trial data from its viral therapy. This metric is an important component of the formulas on System.GURU.Markets that evaluate innovative companies in the oncology sector.
Daily change in the price of a set of shares in a market segment - Cancer cure
Candel Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CADL's performance, which depends on clinical trial results, helps to assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Candel is a biopharmaceutical company developing oncolytic immunotherapy for the treatment of cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects the average fluctuations in this industry, providing context for evaluating Candel stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Candel Therapeutics
Candel Therapeutics' year-over-year performance is a story of developing oncolytic viruses for cancer treatment. Its 12-month market cap depends entirely on progress in clinical trials. Every positive report on the safety and efficacy of its viral immunotherapy is a fundamental step toward creating a new class of anticancer drugs.
Annual dynamics of market capitalization of the market segment - Cancer cure
Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapy for the treatment of cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Candel Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Candel Therapeutics
The value of Candel, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its oncolytic viral immunotherapies, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Oncolytic viruses are an innovative approach to cancer treatment. The performance of this biotech sector, as seen in the chart, reflects investor confidence in new therapeutic approaches. Companies like Candel Therapeutics are conducting clinical trials in this cutting-edge field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Candel Therapeutics, a biopharmaceutical company developing virus therapy for cancer, thrives on lab news. Its shares can soar or collapse based on research data, completely ignoring the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Candel Therapeutics
Shares of Candel Therapeutics, a biopharmaceutical company developing viral cancer therapies, are extremely volatile. Weekly price movements depend entirely on news about clinical trials and scientific publications. The chart below illustrates how short-term scientific developments and investor expectations shape value in innovative oncology.
Weekly dynamics of market capitalization of the market segment - Cancer cure
How does Candel Therapeutics' performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news of its cancer virus therapy, with the overall trend. This helps us understand whether the stock's movement is the result of a unique scientific event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Candel Therapeutics is developing a viral immunotherapy for cancer treatment. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share price movements are driven by clinical trial news, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
CADL - Market capitalization of the company Candel Therapeutics
Candel Therapeutics's market cap reflects investors' bets on its oncolytic virus platform, which is programmed to destroy cancer cells. This clinical-stage biotech's market cap reflects expectations for the success of its research. Its dynamics illustrate the high risk and potential for a breakthrough in immuno-oncology.
CADL - Share of the company's market capitalization Candel Therapeutics within the market segment - Cancer cure
Candel Therapeutics is a clinical-stage biotech company whose market share is based on its oncolytic virus platform for cancer treatment. Its market capitalization reflects investor assessments of the potential of this innovative immunotherapy.
Market capitalization of the market segment - Cancer cure
The chart below shows the combined market capitalization of biotech companies developing viral immunotherapy for cancer. Candel Therapeutics is an innovator in this field. The dynamics in the chart reflect the overall hopes and scientific breakthroughs in this promising, yet high-risk, oncology sector.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new approach to fighting cancer. Candel Therapeutics' market cap reflects investors' faith in its viral immunotherapy platform. The line's dynamics illustrate how cutting-edge science aimed at "training" the immune system to attack tumors is driving value in global biotechnology.
Book value capitalization of the company, segment and market as a whole
CADL - Book value capitalization of the company Candel Therapeutics
Candel Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments in the field of viral immunotherapy for cancer. Growth in this pipeline signals successful funding for clinical trials, which are the primary tangible expression of a biotech company's value.
CADL - Share of the company's book capitalization Candel Therapeutics within the market segment - Cancer cure
For Candel Therapeutics, a company developing viral therapies, its tangible assets are not factories, but cutting-edge laboratories and manufacturing facilities for creating complex biological drugs. The chart reflects its stake in this scientific and manufacturing infrastructure, which is the foundation for the fight against cancer.
Market segment balance sheet capitalization - Cancer cure
Below you can see the overall book value of the biotech sector. Compared to this, Candel Therapeutics, which is developing a cancer virus therapy, looks like a "lightweight." Its value lies in its scientific platform and clinical trial data, not in its large manufacturing plants, which is typical of a company focused on innovation.
Book value of all companies included in the broad market index - GURU.Markets
Candel Therapeutics develops viruses programmed to destroy cancer cells. The company's assets aren't giant factories, but patents, research data, and small production facilities. Their balance sheet represents the value of the "biological weapon" against cancer. Against the backdrop of the material world, Candel creates a living "cure."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Candel Therapeutics
Candel's balance sheet is its cash and patents. Its market cap is a bet on its virus-based immunotherapy technology. The MvsBCap_Co chart shows the vast gap between its modest assets and the high hopes that "good" viruses can defeat cancer.
Market to book capitalization ratio in a market segment - Cancer cure
Candel Therapeutics is developing viruses to fight cancer. This is at the forefront of oncology. Its value lies in its scientific platform and clinical trial data. The chart shows a high speculative valuation of its potential, many times greater than the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Candel Therapeutics is a biotech company developing oncolytic viral immunotherapies for cancer treatment. Its approach involves using modified viruses to destroy cancer cells. The company's value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches in oncology.
Debts of the company, segment and market as a whole
CADL - Company debts Candel Therapeutics
Candel Therapeutics, a biotech company developing cancer immunotherapies, uses debt to finance its research platform. This chart illustrates how the company raises capital to conduct clinical trials of its innovative drugs. In this field, debt is a risky but necessary investment in a potential breakthrough in cancer treatment.
Market segment debts - Cancer cure
Candel Therapeutics is a biotech company developing viral-based immunotherapies for cancer treatment. Clinical trials in this cutting-edge area of oncology require significant and ongoing funding. This chart provides insight into how the company manages its capital to advance its innovative drug candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Candel Therapeutics
Candel Therapeutics, a biotech company developing cancer treatments, requires significant capital. This chart shows its reliance on debt financing to conduct clinical trials. For investors, this is a key risk indicator: if the research is unsuccessful, the company will have no income to repay its debt.
Market segment debt to market segment book capitalization - Cancer cure
Candel Therapeutics develops viruses for cancer immunotherapy. This is a cutting-edge but highly capital-intensive field of biotechnology. Clinical trials are often financed through debt. The chart shows how the company's debt burden for advancing its research compares to the market capitalization and risks of the overall oncology sector.
Debt to book value of all companies in the market
Candel Therapeutics (CADL) is a biotech company developing immunotherapies for cancer treatment. Funding during the R&D stage is typically through equity rather than debt. This chart shows the overall market leverage, clearly demonstrating the contrast between the financial models of innovative biotech companies and mature corporations.
P/E of the company, segment and market as a whole
P/E - Candel Therapeutics
This chart shows the valuation of Candel Therapeutics, a biotech developing virological immunotherapies for cancer treatment. A price-to-earnings ratio (P/E) is not included because the company is in the research stage. Its value is determined solely by investors' faith in the potential of its platform and clinical trial success, not by current financial performance.
P/E of the market segment - Cancer cure
This chart shows the average valuation for biotech companies developing cancer drugs. For Candel Therapeutics, it serves as a backdrop. The company doesn't have a P/E, but this metric reflects investors' overall risk appetite in oncology. It provides context for understanding the valuation based on faith in its scientific platform.
P/E of the market as a whole
Candel Therapeutics is a biopharmaceutical company developing viral immunotherapy for cancer treatment. The company's approach involves using modified viruses to stimulate the immune system against tumors. This risk appetite chart helps understand how investors evaluate innovative oncology platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Candel Therapeutics
Candel Therapeutics is a biotech company developing oncolytic viral immunotherapies for the treatment of cancer. This chart reflects investor expectations for its innovative approach. The valuation is based entirely on hopes for success in clinical trials, as the company strives to transform viruses into effective weapons against tumors.
%20P%2FE%20Candel%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Candel-Therapeutics&v=1772640764913 "Chart of the company's future (projected) P/E Candel Therapeutics")
Future (projected) P/E of the market segment - Cancer cure
Candel Therapeutics develops viruses for cancer immunotherapy that stimulate the immune system to attack tumors. The chart shows the company's expected future profitability relative to the biotech sector. It demonstrates the market's confidence in the potential of their platform to create effective cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772640764966 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Candel Therapeutics is developing virus therapy for cancer treatment. This is a cutting-edge but risky area of medicine. This chart of overall market expectations shows how much investors are willing to invest in biotech. Growing market optimism is making it easier for Candel to raise the capital needed to conduct expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640765006 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Candel Therapeutics
Candel Therapeutics is a biotech company developing immunotherapeutic drugs for the treatment of cancer. Its approach is based on the use of modified viruses to stimulate the immune system against tumors. Financial indicators reflect clinical trial costs. This chart shows the history of the search for breakthroughs in oncology.
Profit of companies in the market segment - Cancer cure
Candel Therapeutics develops viruses to fight cancer by stimulating the immune system to attack tumors. The company is in clinical trials, which is typical for biotech. This chart reflects the cumulative hopes and expenses of oncology R&D, where negative cash flows today represent investments in potential breakthroughs that will change the industry tomorrow.
Overall market profit
Candel Therapeutics is a clinical-stage biotech company developing immunotherapy for cancer. Its value and prospects depend solely on the results of scientific research and regulatory approval. Investors in Candel follow lab news rather than the macroeconomic trends that shape this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Candel Therapeutics
Candel Therapeutics develops oncolytic viral immunotherapies for the treatment of cancer. This chart reflects analyst expectations, which are currently based on the potential of its scientific developments. Progress in clinical trials and positive data are the only drivers for changing future profitability forecasts.
%20profit%20of%20the%20company%20Candel%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Candel-Therapeutics&v=1772640765312 "Graph of future (projected) profit of the company Candel Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Candel Therapeutics is a biotechnology company developing oncolytic viral immunotherapies for the treatment of cancer. This chart shows revenue forecasts for the entire oncology sector. It reflects general expectations for breakthroughs in immunotherapy. This background is important for assessing the potential of Candel's innovative approaches in the fight against malignant tumors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772640765356 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Candel Therapeutics develops virological immunotherapies for the treatment of cancer. Like other early-stage biotech companies, its survival depends on its ability to attract capital for expensive clinical trials. The forecasts in this chart influence the overall investment climate and the availability of funding for risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640765423 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech developing viruses to fight cancer. The company has no sales revenue yet. This chart illustrates how investors assess the potential of its innovative approach to oncology. The high sales estimate, which does not yet exist, indicates confidence in the future commercial success of its drugs.
P/S market segment - Cancer cure
Candel Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapeutics for the treatment of cancer. Its approach is based on the use of modified viruses to stimulate the immune system against tumors. This chart shows the average valuation in the sector, helping to understand how the market views the potential of this innovative oncology platform.
P/S of the market as a whole
Candel Therapeutics is a clinical-stage biotech developing viral immunotherapy for cancer. The company's approach involves coaxing the patient's immune system to attack the tumor. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Candel Therapeutics
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. With no commercial products, its valuation is entirely future-oriented. This chart reflects the market's assessment of the likelihood of success in its clinical trials and the potential future sales of its innovative drugs.
%20P%2FS%20Candel%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Candel-Therapeutics&v=1772640765593 "The graph of the company's future (projected) P/S Candel Therapeutics")
Future (projected) P/S of the market segment - Cancer cure
Candel Therapeutics is a biopharmaceutical company developing oncolytic viral immunotherapies for the treatment of cancer. This chart compares market expectations for its future revenue with those of other companies working on cancer treatments. The valuation reflects investor confidence in its viral platforms for stimulating anti-tumor immunity.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772640765635 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Candel Therapeutics develops viruses to fight cancer. This is at the forefront of oncology. The company's success depends entirely on scientific results. However, the overall optimism in the markets, as illustrated by this chart, creates a favorable environment for funding bold biotech ideas that hold the potential to radically change treatment approaches.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640765707 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Candel Therapeutics
Candel Therapeutics is a biotech company developing viral immunotherapies for cancer treatment. Being in the clinical stage, the company generates revenue not from sales but from grants and potential partnerships. This chart reflects the financial revenue that allows the company to conduct expensive research on its oncology drug candidates.
Sales of companies in the market segment - Cancer cure
Candel Therapeutics is a biotech company developing a new class of cancer immunotherapy based on oncolytic viruses. Its platforms are designed to stimulate the patient's immune system to fight tumors. Currently, revenue is generated through grants and partnerships. This chart shows investment activity in the advanced oncology sector, where Candel is an innovator.
Overall market sales
Candel Therapeutics is a biotech company developing viruses to fight cancer. Its value and prospects depend solely on the success of clinical trials. There is no direct correlation with economic growth, as shown in this chart. However, it does impact the availability of venture capital, which is necessary to fund lengthy and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Candel Therapeutics
Candel Therapeutics is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer. Its approach involves using modified viruses to stimulate the immune system against tumors. This chart reflects analyst expectations for clinical trial results and the commercial potential of viral immunotherapy.
%20sales%20of%20the%20company%20Candel%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Candel-Therapeutics&v=1772640765912 "Schedule of future (projected) sales of the company Candel Therapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Candel Therapeutics is developing viral immunotherapy for the treatment of cancer. This chart shows the overall outlook for the cancer gene therapy sector. It allows one to assess the potential of the company's platform and how potential clinical trial success could impact its valuation relative to overall biotech trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772640766016 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Candel Therapeutics develops immunotherapeutic drugs for the treatment of cancer. This graph, reflecting the investment climate in the biotech sector, is critical for the company. Like many companies in clinical development, Candel depends on its ability to raise capital to fund its research and bring its drugs to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640766084 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Candel Therapeutics
Candel Therapeutics develops innovative cancer treatments based on oncolytic viruses that target tumor cells. The company's business is in the intensive clinical trial phase. This chart illustrates the financial expenditures on research and development, which form the foundation for the creation of potentially breakthrough therapies.
Market segment marginality - Cancer cure
Candel Therapeutics develops oncolytic viral immunotherapies—an innovative approach that uses modified viruses to destroy cancer cells. The company is in the clinical stage, and the data in the chart reflects its investment in R&D. This demonstrates confidence in the platform's potential to deliver high profitability in the future.
Market marginality as a whole
Candel Therapeutics is a biotech company developing oncolytic viral immunotherapies for cancer treatment. The overall profitability picture is irrelevant to them. Their value lies in the potential of their scientific platform. Success depends entirely on the results of clinical trials and the ability of their viruses to effectively fight tumors, not on the state of the economy.
Employees in the company, segment and market as a whole
Number of employees in the company Candel Therapeutics
Candel Therapeutics is a biotech company developing oncolytic viruses for the treatment of cancer. This graph shows the team of scientists and clinicians. The growth of the team is a direct indicator of progress in its clinical programs and investments in the development and production of these complex biologics.
Share of the company's employees Candel Therapeutics within the market segment - Cancer cure
Candel Therapeutics develops oncolytic viral immunotherapies for the treatment of cancer. This chart shows the percentage of leading scientists in virology and oncology the company attracts. This demonstrates its focus on cutting-edge research and the scale of the team working on developing this new class of anticancer drugs.
Number of employees in the market segment - Cancer cure
Candel Therapeutics is a biopharmaceutical company developing virus-based immunotherapeutics for the treatment of cancer. The data in the graph reflects employment in the oncology research sector. The growing number of scientists in this cutting-edge field indicates the search for new modalities to combat difficult-to-treat tumors, in which Candel is an innovator.
Number of employees in the market as a whole
Candel Therapeutics is a biotech company developing immunotherapies for cancer treatment. Its approach is based on the use of modified viruses to stimulate the immune system against tumors. This graph illustrates overall employment, and companies like Candel are at the forefront of science, creating jobs for world-class scientists and researchers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Candel Therapeutics (CADL)
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. Its valuation is based almost entirely on its scientific potential. This chart illustrates a model where intellectual capital dominates. A small team of scientists can create technology worth hundreds of millions of dollars, resulting in an extremely high valuation per employee.
%20of%20the%20company%20Candel%20Therapeutics%20(CADL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Candel-Therapeutics-CADL&v=1772640766417 "Chart of market capitalization per employee (in thousands of dollars) of the company Candel Therapeutics (CADL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Candel Therapeutics is developing oncolytic viral immunotherapy to fight cancer. In biopharma, a company's value is the hope for future drugs. The chart shows how investors evaluate the potential of Candel's developments based on its team of scientists and managers, comparing this "concentration of talent" to the biotech industry average.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772640766478 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Candel Therapeutics develops virological immunotherapies for cancer treatment. Like many biotech companies, its value is based on its research potential. This chart shows the market valuation of intellectual capital, where each scientist contributes to the creation of a platform that could change approaches to cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640766533 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Candel Therapeutics (CADL)
Candel Therapeutics (CADL) is a biopharmaceutical company developing viral immunotherapies for cancer treatment. It's at the cutting edge of science. This chart reflects the "cost of innovation"—the R&D expenses (negative profit) per scientist working on breakthrough treatments. Investors look at this metric to predict future commercial success.
%20Chart%20Candel%20Therapeutics%20(CADL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Candel-Therapeutics-CADL&v=1772640766568 "Company Profit Per Employee (in thousands of dollars) Chart Candel Therapeutics (CADL)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Candel Therapeutics is developing viral immunotherapy for cancer treatment. Their approach uses modified viruses to "train" the immune system. This chart demonstrates the benchmark for biotech staff efficiency. It's important for assessing how effectively Candel's scientific team is leveraging investor capital to advance their research.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772640766600 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. They are trying to "teach" viruses to attack tumors. At this stage, this is pure R&D. This graph doesn't show profit, but rather the amount of capital the company is burning through per scientist in their quest to create a breakthrough drug. It's a bet on a future where a single success will recoup all costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640766619 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Candel Therapeutics (CADL)
Candel Therapeutics is a biotech company developing viruses to fight cancer (oncolytic virus therapy). This chart reflects its focus on research. Low revenue per employee is typical for clinical-stage companies, where the entire team is focused on proving the technology's effectiveness rather than on selling it.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Candel-Therapeutics-CADL&v=1772640766717 "Sales chart per company employee Candel Therapeutics (CADL)")
Sales per employee in the market segment - Cancer cure
Candel Therapeutics (CADL) is a biotech company developing viral immunotherapies (using modified viruses) for the treatment of cancer. This graph shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform compared to other companies working in the field of oncolytic viruses.
Sales per employee for the market as a whole
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. They "reprogram" viruses to attack tumors. They are a clinical-stage R&D company. This graph is close to zero, as the company has no commercial revenue. It reflects ongoing investment in research staff in anticipation of breakthrough clinical trial results.
Short shares by company, segment and market as a whole
Shares shorted by company Candel Therapeutics (CADL)
Candel Therapeutics is a biotech company developing cancer treatments based on "viral immunotherapy" (using viruses to attack tumors). This chart shows bearish bets. "Shorting" such early-stage biotechs is a bet that their scientific platform will prove ineffective in clinical trials or fail to receive FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Candel-Therapeutics-CADL&v=1772640766873 "Short Shares Chart for the Company Candel Therapeutics (CADL)")
Shares shorted by market segment - Cancer cure
Candel Therapeutics (CADL) is a clinical-stage biotech developing oncolytic viruses (viruses that kill cancer) for the treatment of solid tumors. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Candel, which relies on capital, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Candel Therapeutics (CADL) is a clinical-stage biopharmaceutical company developing viral immunotherapy for cancer. It's a high-risk bet on a scientific breakthrough. This market pessimism chart is an indicator of "risk appetite." When investors are afraid, they don't want to "buy the dream" and sell CADL shares in favor of stability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Candel Therapeutics (CADL)
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. This is a speculative R&D bet. This chart measures the level of hope. It shows when the stock is "overheated" (overbought) on positive data or "oversold" amid delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Candel-Therapeutics-CADL&v=1772640767081 "RSI 14 indicator chart for the company's stock Candel Therapeutics (CADL)")
RSI 14 Market Segment - Cancer cure
Candel Therapeutics is a biotech company developing viral immunotherapy for cancer treatment. They use modified viruses to stimulate the immune system to attack tumors. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
Candel Therapeutics, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like CADL are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CADL (Candel Therapeutics)
Candel Therapeutics is a biotech company developing viral immunotherapy (oncolytic viruses)—an approach that uses modified viruses to destroy cancer. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this sophisticated R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CADL-Candel-Therapeutics&v=1772640767420 "A chart showing analyst consensus forecasts for the expected stock price. CADL (Candel Therapeutics)")
The difference between the consensus estimate and the actual stock price CADL (Candel Therapeutics)
Candel Therapeutics is a biotech company that reprograms viruses (oncolytic virotherapy) to attack and destroy cancer tumors from the inside. This chart measures the gap between the current stock price and the consensus target price. It shows how much confidence experts have in this cutting-edge immunotherapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CADL-Candel-Therapeutics&v=1772640767444 "A chart showing the difference between the consensus forecast and the actual stock price. CADL (Candel Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Candel Therapeutics is a biotech company developing "oncolytic viruses"—genetically engineered viruses programmed to seek out and kill cancer cells. This chart shows general expectations for the oncology sector, reflecting whether experts believe this cutting-edge R&D will be commercially successful.
Analysts' consensus forecast for the overall market share price
Candel Therapeutics is a biotech company developing oncolytic viruses (viruses that kill cancer) and immunotherapies for the treatment of difficult-to-treat tumors. This chart shows the overall risk appetite. For Candel, a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech company specializing in point-of-care immunotherapy. They develop viruses (oncolytic viruses) that are injected directly into tumors to awaken the immune system to fight cancer. This graph is a pure reflection of their science. Its dynamics depend entirely on their progress in clinical trials.
AKIMA Market Segment Index - Cancer cure
Candel (CADL) is a clinical-stage biotech and a pioneer in immunotherapy; the company develops oncolytic viruses (viruses that kill cancer) for the treatment of solid tumors. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (R&D platform) model (CADL) differentiate it from the average pharma company?
The AKIM Index for the overall market
Candel Therapeutics is a biotech company developing viral immunotherapies for the treatment of solid tumors (brain and pancreatic cancer). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story compares to the overall economic trends affecting oncology.
